Condition: Multiple System Atrophy · Sponsor: Teva Branded Pharmaceutical Products R&D LLC
The primary objective of the study is to evaluate the efficacy of TEV-56286 administered orally for the treatment of adult participants with Multiple System Atrophy (MSA). A secondary objective of the study is to evaluate specific efficacy parameters of TEV-56286. Another secondary objective is to evaluate the safety and tolerability of TEV-56286. The planned study period per participant is 56 weeks including a screening period (up to 4 weeks), a 48-week double-blind treatment period, and a follow-up visit (approximately 4 weeks after the end of the double-blind treatment period). The study duration will be approximately 27 months.
This description comes directly from the study's public registry record.
Teva U.S. Medical Information · 1-888-483-8279 · USMedInfo@tevapharm.com
Always discuss trial participation with your own doctor first.
| Teva Investigational Site 15554 | La Jolla, California, United States | Recruiting |
| Teva Investigational Site 15545 | Los Angeles, California, United States | Not Yet Recruiting |
| Teva Investigational Site 15547 | Washington D.C., District of Columbia, United States | Recruiting |
| Teva Investigational Site 15544 | Boca Raton, Florida, United States | Active Not Recruiting |
| Teva Investigational Site 15555 | Tampa, Florida, United States | Recruiting |
| Teva Investigational Site 15550 | Chicago, Illinois, United States | Recruiting |
| Teva Investigational Site 15546 | Kansas City, Kansas, United States | Recruiting |
| Teva Investigational Site 15736 | Boston, Massachusetts, United States | Recruiting |
| Teva Investigational Site 15870 | Farmington Hills, Michigan, United States | Not Yet Recruiting |
| Teva Investigational Site 15552 | Rochester, Minnesota, United States | Recruiting |
| Teva Investigational Site 15549 | New York, New York, United States | Recruiting |
| Teva Investigational Site 15551 | New York, New York, United States | Recruiting |
+ 49 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06568237